University of Barcelona

• On the 19th September 2009, ULS signed an exclusive license with the University of Barcelona for the development and commercialisation of novel peptide analogues with infectious disease applications.

• The peptides identified thus far by the University of Barcelona possess a novel structure and appear to have a broad spectrum of activity towards both Gram negative and Gram positive organisms.

• Further peptide derivatives will now be synthesised and screened against a panel of organisms for improvements in activity.

• Biophysical experiments are also planned to establish the exact mode of action of these unusual peptides.